TL;DR
Small-for-gestational-age (SGA) newborns are at higher risk for adult cardiovascular diseases, partly due to endothelial dysfunction. This study reveals that in SGA infants, epigenetic changes in umbilical vein endothelial cells (HUVECs) lead to increased angiogenesis, driven by the gene CD44. This CD44 upregulation is orchestrated by specific enhancers and the transcription factor AP-1, offering potential therapeutic targets.
What Problem Does This Paper Address?
Infants born small for their gestational age (SGA) face a significantly increased risk of developing cardiovascular and metabolic diseases later in life. A key factor contributing to this is endothelial dysfunction, where the cells lining blood vessels don't function properly. While this association is known, the precise molecular mechanisms driving this dysfunction in SGA infants remain unclear. This paper aims to unravel these mechanisms by investigating the epigenetic landscape of human umbilical vein endothelial cells (HUVECs) from SGA newborns, focusing on how these changes lead to altered cellular behavior and contribute to long-term health risks.
Methods
The researchers employed a multi-omics approach to dissect the cellular and molecular differences in HUVECs from SGA and appropriate-for-gestational-age (AGA) newborns. Key techniques included:
- Phenotype Characterization: Assessed functional differences in HUVECs through assays for angiogenesis (tube formation), migration (Transwell and scratch wound healing), proliferation (EdU and CCK8 assays), and glucose consumption.
- Transcriptome Analysis (RNA-Seq): Mapped gene expression profiles to identify differentially expressed genes (DEGs) between SGA and AGA HUVECs.
- Chromatin Accessibility Mapping (ATAC-Seq): Identified regions of open chromatin, indicating active regulatory elements like enhancers and promoters, to understand how gene expression is controlled epigenetically.
- Chromatin Interaction Analysis (Hi-C and 3C-qPCR): Investigated how enhancers physically interact with gene promoters to regulate gene expression.
- ChIP-Seq: Used to identify the binding sites of key transcription factors, specifically AP-1 subunits (FOS and JUN), at regulatory regions.
- CRISPR interference (CRISPRi): Used to specifically silence the activity of identified enhancers and the CD44 promoter to assess their functional impact.
- siRNA: Employed to knock down CD44 expression and evaluate its role in HUVEC function.
- Western Blot and RT-qPCR: Used to validate protein and mRNA expression levels of key genes and signaling molecules (e.g., CD44, p-ERK1/2, p-eNOS).
- Inhibitor Treatment: Utilized a small molecule inhibitor (T-5224) to block AP-1 activity and assess its effect on CD44 expression and HUVEC function.
Datasets
The study utilized primary human umbilical vein endothelial cells (HUVECs) isolated from:
- 12 SGA neonates
- 9 AGA neonates (control group)
Additionally, they integrated public ENCODE ChIP-Seq datasets for histone modifications (H3K4me1, H3K4me3, H3K27ac) and transcription factors (FOS, JUN) in HUVECs, as well as public Hi-C data for HUVECs.
Key Insights and Ideas
- SGA HUVECs are "hyperactive": The most striking finding is that HUVECs from SGA infants exhibit enhanced angiogenesis, migration, and proliferation compared to their AGA counterparts. This suggests an altered, potentially pathological, cellular state from birth.
- CD44 is the central player: The study strongly implicates CD44 as the key driver of this SGA-associated HUVEC dysfunction. Its upregulation is consistently linked to the observed hyperangiogenic phenotype.
- Epigenetic control of CD44: The research goes beyond simply identifying CD44 upregulation. It reveals that this is driven by epigenetic mechanisms, specifically increased chromatin accessibility at three distinct enhancers that interact with the CD44 promoter.
- AP-1 as the conductor: The transcription factor AP-1 is identified as a crucial regulator. It binds to both the CD44 promoter and its associated enhancers, reinforcing their interaction and ultimately driving elevated CD44 expression. This highlights a specific molecular pathway for epigenetic regulation.
- Therapeutic potential: By pinpointing CD44, its regulatory enhancers, and AP-1, the study opens avenues for therapeutic interventions aimed at restoring normal endothelial function in SGA individuals.
Key Results
- SGA-HUVECs showed significantly increased tube formation, migration, and proliferation compared to AGA-HUVECs.
- RNA-Seq identified 399 differentially expressed genes (DEGs) in SGA-HUVECs, with CD44 being a major upregulated gene.
- ATAC-Seq revealed 1,203 differentially accessible regions (DARs), with a significant increase in accessibility at enhancers in SGA-HUVECs.
- CRISPRi-mediated knockdown of CD44 or its regulatory enhancers significantly reduced the hyperangiogenic phenotype of SGA-HUVECs.
- Overexpression of CD44 in AGA-HUVECs mimicked the SGA phenotype, further confirming CD44's role.
- AP-1 (specifically FOS and JUN) binding was enriched at the CD44 promoter and enhancer regions in SGA-HUVECs.
- Inhibition of AP-1 with T-5224 reduced CD44 expression and alleviated the hyperangiogenesis of SGA-HUVECs.
Limitations and Future Work
- Sample Size: The authors acknowledge that the relatively small sample size may limit the generalizability of their findings, suggesting a need for larger cohorts to confirm reproducibility.
- HUVEC Representation: HUVECs are primary cells, but they may not fully represent all adult vascular cells, as endothelial cell characteristics can vary with age and location. In vivo models or adult primary endothelial cells are suggested for further validation.
- Molecular Mechanisms: While the study identifies CD44's interaction with ERK/eNOS signaling, the precise molecular mechanisms are not fully resolved and warrant further investigation.
- Aging Connection: The potential link between elevated CD44 in SGA infants and early vascular aging is an exciting avenue for future research, exploring whether this upregulation follows an age-dependent pattern.
- CD44 Surface Interactions: Future studies should explore how CD44, as a surface protein, coordinates with other proteins (like LYVE1) to regulate endothelial function.
- Metabolic Reprogramming: Further investigation into whether SGA-HUVECs undergo metabolic reprogramming, particularly regarding glycolysis, is crucial.
Summary updated